Tuesday, March 28, 2023
| Patients | ||
|---|---|---|
| Characteristic | n | % |
| Full cohort, n | 295 | 100 |
| Recipient age, median (range) | 66 (6-76) | |
| Recipient sex | ||
| Female | 117 | 40 |
| Male | 178 | 60 |
| HCT-CI score | ||
| 0 | 83 | 28 |
| 1-2 | 81 | 27 |
| 3+ | 120 | 40 |
| Missing | 11 | 4 |
| Type of AML (clinically defined) | ||
| De novo | 173 | 59 |
| Secondary | 91 | 31 |
| Therapy-related | 31 | 11 |
| Cytogenetics* | ||
| Normal | 136 | 46 |
| Core binding factor | 6 | 2 |
| Complex karyotype | 41 | 14 |
| Other | 112 | 38 |
| 2017 ELN risk group | ||
| Favorable | 53 | 18 |
| Intermediate | 85 | 29 |
| Adverse | 152 | 52 |
| Missing | 5 | 2 |
| Initial therapy | ||
| Intensive induction | 249 | 84 |
| Non-intensive induction | 46 | 16 |
| Reinduction | ||
| Yes | 90 | 31 |
| No | 204 | 69 |
| Missing | 1 | 0.3 |
| Remission quality | ||
| CR with hematologic recovery | 225 | 75 |
| CRi | 67 | 23 |
| Missing | 1 | 0.3 |
| Donor type | ||
| Matched related | 54 | 18 |
| Matched unrelated | 154 | 52 |
| Mismatch related | 7 | 2 |
| Mismatch unrelated | 29 | 10 |
| Haploidentical | 51 | 17 |
| Conditioning regimen | ||
| Myeloablative | 28 | 9 |
| Reduced intensity | 267 | 91 |
| T-cell depletion | 25 | 9 |
| Stem cell source | ||
| Peripheral blood | 216 | 73 |
| Bone marrow | 71 | 24 |
| Umbilical cord blood | 8 | 3 |
Table 1. Cohort characteristics
Shown are the pretransplant characteristics of the 295 patients included in the cohort. HCT-CI: hematopoietic cell transplant comorbidity index score. CRi denotes complete remission with incomplete recovery of at least 1 hematopoietic cell lineage.
ELN, European Leukemia Network.
* Core binding factor: inv(16) or t(8;21); complex karyotype: 3 or more chromosomal abnormalities within a single clone.
Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 1.00 ABIM MOC points
This activity is intended for hematologists, oncologists, internists, geriatricians, and other clinicians caring for older patients with acute myeloid leukemia (AML).
The goal of this activity is that the learner will be better able to describe factors that drive outcomes of allogeneic hematopoietic cell transplantation (HCT) for AML in older patients, according to a targeted mutational genomic analysis of paired diagnostic and available remission specimens in a multi-institutional cohort of 295 patients with AML aged ≥ 60 years who underwent HCT in first complete morphologic remission (CR1).
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 6/16/2022
Valid for credit through: 6/16/2023
processing....
| « Return to: Impact of Diagnostic Genetics on Remission MRD and Transplantation Outcomes in Older Patients With AML |
